CorMedix (CRMD) to Release Earnings on Tuesday

CorMedix (NASDAQ:CRMD) is projected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect CorMedix to post earnings of $0.05 per share and revenue of $27.46 million for the quarter.

CorMedix Price Performance

Shares of CRMD stock opened at $10.71 on Monday. The firm has a market cap of $649.85 million, a P/E ratio of -13.22 and a beta of 1.53. CorMedix has a 1-year low of $3.03 and a 1-year high of $13.85. The firm’s 50-day simple moving average is $10.54 and its 200-day simple moving average is $9.54.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CRMD. Leerink Partners began coverage on shares of CorMedix in a report on Friday. They set an “outperform” rating and a $18.00 price objective on the stock. Leerink Partnrs upgraded shares of CorMedix to a “strong-buy” rating in a report on Friday. Royal Bank of Canada raised their price target on shares of CorMedix from $11.00 to $12.00 and gave the company an “outperform” rating in a report on Thursday, December 19th. Finally, D. Boral Capital restated a “buy” rating and issued a $15.00 price target on shares of CorMedix in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, CorMedix currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.